14335-78-5

Basic information

• Product Name: 2(3H)-Furanone, 5-(3,4-dimethoxyphenyl)dihydro-
• CAS NO: 14335-78-5
• Molecular Formula: C12H14O4
• Molecular Weight: 222.241
• Mol File: 14335-78-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 2(3H)-Furanone, 5-(3,4-dimethoxyphenyl)dihydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 2(3H)-Furanone, 5-(3,4-dimethoxyphenyl)dihydro-(14335-78-5)
• EPA Substance Registry System: 2(3H)-Furanone, 5-(3,4-dimethoxyphenyl)dihydro-(14335-78-5)

Safety Data

• Hazardous Substances Data: 14335-78-5(Hazardous Substances Data)

Upstream product

• 623-11-0 1-methyl-4-nitrosobenzene 
• 5333-34-6 3-(3,4-dimethoxybenzoyl)propionic acid 
• 91-16-7 1,2-dimethoxybenzene 
• 76233-58-4 3,4-dichloro-5-(3,4-dimethoxy-phenyl)-5H-furan-2-one 
• 13575-74-1 4-(3,4-dimethoxyphenyl)butanoic acid 
• 91496-51-4 1-(3,4-dimethoxy-phenyl)-but-3-yn-1-ol 

Relevant articles and documents

Catalytic Redox Chain Ring Opening of Lactones with Quinones to Synthesize Quinone-Containing Carboxylic Acids

Catalytic ring opening of five- to eight-membered lactones with quinones is achieved through a redox chain mechanism. With low loading of a simple metal triflate Lewis acid catalyst and a chain initiator, C-H bonds of many quinones were efficiently functionalized with carboxylic acid-containing side chains. This method also features 100% atom economy and wide substrate scope. A novel route to the anti-asthma drug Seratrodast was developed. Mechanism study suggests that the redox chain reaction likely undergoes a carbocation intermediate.

Reactivity and acid-base behavior of ring-methoxylated arylalkanoic acid radical cations and radical zwitterions in aqueous solution. Influence of structural effects and pH on the benzylic C-H deprotonation pathway

A product and time-resolved kinetic study of the one-electron oxidation of ring-methoxylated phenylpropanoic and phenylbutanoic acids (Ar(CH 2)nCO2H, n = 2, 3) has been carried out at different pH values. Oxidation leads t

COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS

Enantiomerically enriched disubstituted tetrahydrofurans, tetrahydrothiophenes, pyrrolidines and cyclopentanes are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i.e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase. It has been determined that 5-lipoxygenase activity, oral availability, and stability in vivo (for example, glucuronidation rate) can vary significantly among the optical isomers of the disclosed compounds.